Generics

Generic Lupron is used for the palliative treatment of advanced prostate cancer.

Wyost and Jubbonti are the first and only interchangeable denosumab biosimilars in the United States.

Bio-Thera is responsible for the development and manufacturing of the product, while Hikma is responsible for the commercialization in the United States.

The agreement includes proposed biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab) and an additional early-stage undisclosed biosimilar candidate.

SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same.

Varenicline tablets are indicated for use as an aid to smoking cessation treatment.

Clophosphamide has been approved for certain kinds of cancer.

Paclitaxel is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and locally advanced or metastatic non-small cell lung cancer.